Chromocell Therapeutics Operating Income

As of the most recent data (June 2026), CHRO shows a operating income of $-19M. That compares with $-8.9M in the prior-year period — down 113.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CHRO's operating income is now $-19M (was $-8.9M) — a 113.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Chromocell Therapeutics is outperforming or lagging.

Tracking CHRO's operating income over time shows whether Chromocell Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-19M That compares with $-8.9M in the prior-year period — down 113.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Chromocell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-19M) with ownership activity and broader fundamentals.